I have genital herpes; what is the recommended antiviral treatment and management?

Management of Genital Herpes

For genital herpes, start oral antiviral therapy with either valacyclovir 1000 mg twice daily or acyclovir 400 mg five times daily for 7–10 days for the first episode, then offer all patients the choice between daily suppressive therapy (valacyclovir 500 mg once daily or acyclovir 400 mg twice daily) or episodic treatment for recurrences. 1

Initial Episode Treatment

For your first clinical episode of genital herpes, begin oral antiviral therapy immediately:

• Valacyclovir 1000 mg twice daily for 7–10 days is the preferred first-line option due to superior bioavailability and twice-daily dosing that improves adherence 2, 3
• Acyclovir 400 mg five times daily for 7–10 days is an effective alternative, though the five-times-daily schedule may reduce compliance 1, 4
• Acyclovir 200 mg five times daily for 5–10 days can be used when higher dosing is not feasible 4

Continue treatment for the full 7–10 days based on clinical severity; extend duration if lesions have not completely healed 1, 3

Long-Term Management: Two Pathways

All patients should be informed about both suppressive and episodic therapy options and offered suppressive therapy. 1

Suppressive Therapy (Daily Prevention)

Daily suppressive antiviral therapy is recommended for:

• Patients with ≥6 recurrences per year 5
• Anyone wishing to reduce transmission risk to sexual partners 1
• Individuals seeking to minimize recurrence frequency (reduces episodes by at least 75%) 5

Suppressive regimens:

• Valacyclovir 500 mg once daily (preferred for once-daily convenience) 5, 2
• Acyclovir 400 mg twice daily 1, 5

Critical suppressive therapy facts:

• Suppressive therapy reduces viral shedding and transmission in heterosexual couples, and the same mechanism applies to men who have sex with men, women who have sex with women, and transgender persons 1
• However, suppressive therapy does NOT work to decrease transmission in persons with HIV/HSV-2 coinfection 1
• Suppression does not eliminate asymptomatic viral shedding or eradicate latent virus 5
• Patients must continue safer sex practices, including condom use, even while on suppressive therapy 5
• After one year of continuous suppressive therapy, consider a treatment interruption to reassess the recurrence rate 5

Episodic Therapy (Treat Outbreaks as They Occur)

For patients who prefer to treat only symptomatic recurrences:

• Valacyclovir 500 mg twice daily for 3–5 days (FDA-approved 3-day regimen available) 2, 3
• Acyclovir 400 mg three times daily for 5 days 1, 3

Start episodic therapy at the first sign of prodromal symptoms or lesion appearance for maximum benefit 3

Special Populations

HIV-Infected Patients

HIV-infected individuals require higher doses and longer durations than immunocompetent patients: 5

First episode:

• Acyclovir 400 mg orally five times daily for 7–10 days (or until lesions resolve) 5
• Acyclovir 200 mg five times daily for 7–10 days is an alternative when higher dosing is not feasible 5
• Intravenous acyclovir is indicated for severe disease, extensive lesions, or multi-dermatomal involvement 5

Recurrent episodes:

• Acyclovir 400 mg three to five times daily until clinical resolution 5

Suppressive therapy:

• Valacyclovir 500 mg twice daily 5
• Acyclovir 400 mg twice daily 5

Critical HIV-specific pitfalls:

• Never use immunocompetent dosing regimens (lower doses, shorter courses) in HIV-infected patients 5
• Topical acyclovir should never be used in HIV-infected patients—it is substantially less effective than oral therapy 5
• Monitor for acyclovir-resistant HSV strains, which are more common in immunocompromised hosts receiving suppressive therapy 5
• If lesions persist or worsen after 7–10 days of appropriate therapy, suspect resistance and obtain viral culture with susceptibility testing 5

Pregnancy

For pregnant women with a history of genital herpes:

• Start suppressive antiviral prophylaxis at 36 weeks of gestation and continue until delivery to reduce the need for cesarean section due to active lesions 6, 4, 7
• Acyclovir 400 mg three times daily or valacyclovir 500 mg twice daily 4
• Offer elective cesarean delivery to patients with active lesions at the time of labor to reduce neonatal HSV exposure 6, 7

For recurrent episodes during pregnancy, treat with acyclovir or valacyclovir if symptoms warrant (duration and severity justify treatment) 4

Diagnosis

Diagnosis should be confirmed with:

• Type-specific polymerase chain reaction (PCR) from active lesions (preferred method) 6, 7, 8
• Viral culture of active lesions 6
• Type-specific serologic testing (HSV-2 antibody) for persons with genital symptoms consistent with herpes but no active lesions, or those told they have genital herpes without virologic confirmation 1

Serologic screening is NOT recommended for asymptomatic people with low pretest probability (few lifetime partners, no known HSV-2 positive partners, no genital symptoms) or for routine screening of pregnant women 1

Transmission Prevention

Counsel all patients on transmission reduction strategies:

• Suppressive antiviral therapy reduces (but does not eliminate) transmission to uninfected partners 1, 6
• Avoid sexual contact during symptomatic outbreaks 6
• Use condoms consistently, even during suppressive therapy and asymptomatic periods 5, 6
• Asymptomatic viral shedding is common and represents the most frequent mode of transmission 8

Acyclovir-Resistant Herpes

For suspected or confirmed acyclovir-resistant HSV (rare in immunocompetent patients, more common in immunocompromised):

• Foscarnet is required, as valacyclovir and famciclovir will also be ineffective 5
• Case reports suggest brincidofovir, imiquimod, and topical cidofovir may be useful 1
• Helicase-primase inhibitors (pritelivir) are under investigation but not yet FDA-approved 1

Key Pitfalls to Avoid

• Never use topical acyclovir—it is substantially less effective than oral therapy and does not improve systemic symptoms 5, 9
• Antiviral therapy does not eradicate latent HSV, prevent future recurrences after discontinuation, or eliminate asymptomatic shedding 5
• Do not apply immunocompetent dosing to HIV-infected or immunocompromised patients 5
• Suppressive therapy does not prevent transmission in HIV/HSV-2 coinfected persons 1
• Routine serologic screening is not recommended for asymptomatic individuals or pregnant women 1